RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), is a clinical- stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47, today announced that it has extended its collaboration agreement with Moffitt Cancer Center (“Moffitt”) for an additional year.
Helix BioPharma & Moffitt Cancer Center Immunotherapy Collaboration – 8 12 20